[BIO USA] Lotte Biologics and Otimopharma Sign Antibody Manufacturing Contract

Production of Drug Substance for Antibody New Drug "Zenkistomic"

Lotte Biologics announced on the 18th (local time) that it has signed a contract manufacturing agreement for antibody drugs with Otimopharma.

Lotte Biologics officials (from right: Brett Buddis, Head of Global PMO at Lotte Biologics; Shin Youl, Head of Global Strategy Office; James Park, CEO) and Otimopharma executives are taking a commemorative photo after signing an antibody production contract at the 2025 Bio International Convention 2025 (BIO USA) held in Boston, USA on the 17th (local time). Photo by Choi Taewon

Through this agreement, Lotte Biologics will produce the drug substance (DS) for Otimopharma's antibody new drug "Zenkistomic" at its Syracuse Bio Campus in New York, USA.

Lotte Biologics provides contract development and manufacturing organization (CDMO) services at the Syracuse Bio Campus, offering everything from cell line development to large-scale contract manufacturing of pharmaceuticals. In addition, the company is aiming to begin operation of its first plant at the Songdo Bio Campus in 2027. The first plant will be a large-scale biopharmaceutical production facility with a production capacity of 120,000 liters.

Lotte Biologics is strengthening its position in the CDMO market by expanding partnerships with various global bio companies in Asia, Europe, and other regions.

Furthermore, to provide customized end-to-end services for clients, the company is entering into strategic business agreements with global contract development organizations (CDOs) and drug product (DP) companies, offering tailored CDMO solutions that cover the entire drug development cycle from the early stages of new drug development to commercialization.

James Park, CEO of Lotte Biologics, stated, "This contract serves as an opportunity to reaffirm Lotte Biologics' competitiveness as a CDMO company in the global antibody drug market. We will strive to become a company that provides greater value to our partners and patients, going beyond the supply of high-quality pharmaceuticals that meet global standards."

Joseph Schultz, Vice President of Otimopharma, said, "This production collaboration will serve as an important milestone in promoting the development of Zenkistomic quickly and precisely. Based on Lotte Biologics' outstanding biopharmaceutical manufacturing capabilities, we will further strengthen our preparations for IND submission and the initiation of clinical trials, enabling us to move to the next stage even faster."

Meanwhile, the signing ceremony was held at the Lotte Biologics booth inside the Boston Convention and Exhibition Center, where the 2025 Bio International Convention (BIO USA) is taking place. Key executives, including James Park, CEO of Lotte Biologics; Shin Youl, Head of Global Strategy Office; and Joseph Schultz, Vice President of Otimopharma, attended the event.